Potential adverse effects, such as gastrointestinal issues and long-term safety concerns, also limit widespread adoption
This timeliness is especially important as demand for GLP-1s grows, both for approved indications and off-label use
If your primary health goals are metabolic, including insulin sensitivity, liver health, and body composition rather than specifically cardiovascular, retatrutide broader mechanism of action may deliver more comprehensive benefits
Search open Phase 3 sites at ClinicalTrials.gov using the term "retatrutide," or use Eli Lilly's Lilly's trial portal at trials.lilly.com
By harnessing the power of a GLP-1, GIP, and glucagon receptor agonist simultaneously, this medication is being studied for effects on appetite, metabolic signaling, and energy balance
If you can tolerate weekly dosing, the evidence strongly supports sticking with it